Neurogene
Neurogene was founded to develop innovative therapies for rare neurological disorders.
The firm's lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technologies to develop treatments for diseases not well served by gene therapy.
Latest Neurogene News & Features
16 January 2024
19 December 2023
13 February 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze